Meridigen Biotech Co., Ltd.

DUBLIN, July 14, 2023 /PRNewswire/ -- The "Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. With an extensive focus on 65+ companies and 70+ pipeline drugs, this report provides a detailed analysis of the current scenario and growth prospects across the indication. The report encompasses a comprehensive overview of the pipeline drug profiles, covering both clinical and nonclinical stage products. Additionally, it includes a thorough assessment of therapeutics, considering product type, stage, route of administration, and molecule type. Inactive pipeline products in this space are also highlighted, providing a holistic view of the COPD pipeline landscape. To provide a comprehensive understanding, this report outlines the present scenario and growth prospects in the COPD field. It offers detailed insights into the disease overview and treatment guidelines for Chronic Obstructive Pulmonary Disease, setting the stage for a deeper exploration of the pipeline landscape. Furthermore, the report delves into the commercial assessment and clinical assessment of the pipeline products under development. It provides detailed descriptions of each drug, including their mechanisms of action, clinical studies, NDA approvals (if any), and comprehensive product development activities. This encompasses technology, COPD collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant product-related details. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Disease Emerging Drugs Chapters This segment of the Chronic Obstructive Pulmonary Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Chronic Obstructive Pulmonary Disease Emerging Drugs Benralizumab: AstraZeneca Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin-5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transduction. Dupilumab: Sanofi Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL) that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reactions, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is under investigation for its potential therapeutic use in chronic obstructive pulmonary disease and is currently in the Phase III stage of development. Tezepelumab: Amgen Tezepelumab (Tezspire) is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Specifically, TEZSPIRE targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic, and other types of airway inflammation associated with severe asthma. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses, and other airborne particles. Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control. Tezspire is being developed in collaboration with AstraZeneca and is currently being evaluated in Phase II to treat patients with chronic obstructive pulmonary disease. SNG001: Synairgen SNG001 boosts antiviral responses in the lungs, has a beneficial effect on lung function, and in more difficult to treat patients, improves asthma control during cold infections. The drug is currently being evaluated in the Phase II stage of development to treat patients with COPD. GSK3923868: GlaxoSmithKline GSK3923868, is a PI4kb inhibitor in development as a treatment for viral COPD exacerbations. It belongs to the class of antiasthmatics. The drug acts as a 1-phosphatidylinositol-4-kinase inhibitor. Currently, the drug is in Phase I of its clinical trial evaluation for the treatment of chronic obstructive pulmonary disease. Chronic Obstructive Pulmonary Disease: Therapeutic Assessment This segment of the report provides insights about the different Chronic Obstructive Pulmonary Disease drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Chronic Obstructive Pulmonary Disease There are approx. 65+ key companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca. Phases Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Intramuscular Molecule Type Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Product Type Chronic Obstructive Pulmonary Disease Report Insights Chronic Obstructive Pulmonary Disease Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Key Players Sanofi AstraZeneca Amgen Synairgen GlaxoSmithKline Eisai Meridigen Biotech Chiesi EmeraMed Limited Verona Pharma Tetherex Pharmaceuticals Mereo BioPharma Key Products Lemborexant UMC119-06 CHF5259 Emeramide Ensifentrine SNG001 GSK3923868 Benralizumab Dupilumab Tezepelumab SelK2 BCT197 For more information about this clinical trials report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Cerebral palsy is a condition or disorder responsible for impairment of movement and coordination in muscles of the body that may lead to permanent loss of movement in the body. It may further impact sensation, swallowing, vision, speaking, and hearing faculties in many cases. Common symptoms of cerebral palsy include continuous drooling, muscle stiffness, weakness, tremors, poor coordination, and neurological complications, such as, intellectual disability, seizures, etc. Read Report Overview - According to CDC, in the U.S., 1.5 to 4 in every 1000 children are diagnosed with cerebral palsy. The disorder mostly arises due to abnormal development or damage of those parts of the brain which are responsible for controlling movements, posture, and balance. Cerebral palsy, most commonly, appears before birth, nevertheless, its complications may also arise during child birth or soon after birth. Different risks factors involved with this condition include methylmercury exposure during pregnancy, preterm birth, infections during pregnancy — rubella, German measles, toxoplasmosis, and herpes simplex, difficulties in delivery, asphyxia neonatorum, and intracranial hemorrhage. Rise in incidence of cerebral palsy can be attributed to multiple factors, such as, premature birth or low weight at the time of birth, multiple child births, and incidence of infectious diseases at the time of pregnancy. Further, health conditions of the mother may also lead to cerebral palsy in the child through conditions such as thyroid, seizures, intellectual disability, and so on. Request Brochure of Report - Rapid growth of the cerebral palsy treatment market can be attributed to increase in incidence of cerebral palsy, coupled with rise in awareness among parents regarding complications of cerebral palsy and availability of various treatments options in the market. However, side effects associated with the drugs are expected to limit the growth of the cerebral palsy treatment market in the next few years. The global cerebral palsy treatment market can be segmented based on drug type, type of cerebral palsy, and region. In terms of drug type, the cerebral palsy treatment market can be categorized into anticonvulsants drugs, anticholinergic drugs, antidepressants drugs, anti-inflammatory drugs, and others. Based on type of cerebral palsy, the market can be classified into dyskinetic cerebral palsy, spastic cerebral palsy, hypotonic cerebral palsy, mixed cerebral palsy, and ataxic cerebral palsy. Request for Custom Research - In terms of geography, the global cerebral palsy treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is likely to account for a major share of the global cerebral palsy treatment market in 2018 due to increase in investment in R&D, rise in awareness among people regarding mental health, favorable regulations and reimbursement policies implemented by governmental bodies, and growing health care expenditure in the region. Europe, followed by Asia Pacific, is projected to be highly lucrative markets for cerebral palsy treatment in the near future. The cerebral palsy treatment market in Asia Pacific is expected to grow rapidly during the forecast period. Increasing population and growing support in terms of investment from both public and private sectors are expected to drive the market in the region in the near future. Pre Book Cerebral Palsy Treatment Market Report at Furthermore, increasing awareness among people regarding complications and treatment of cerebral palsy, coupled with rising technological penetration, is anticipated to further support the growth of the cerebral palsy treatment market. The cerebral palsy treatment market in Middle East & Africa and Latin America is likely to grow substantially during the forecast period due to introduction of favorable governmental norms and increase in expenditure on health care by both public and private bodies. Key players operating in the cerebral palsy treatment market include Allergen Plc., Cellular Biomedicine Group, Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Abbott, Acorda Therapeutics, Inc., Medtronic, Meridigen Biotechnology, and GW Pharmaceuticals Plc. Browse More Trending Reports by Transparency Market Research: Stem Cell Gun Devices Market: Revascularization Devices Market: Anesthesia Disposables Market: About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: